Outlook
Description

Founded in 2010
Nasdaq listed (ticker: OTLK)
Clinical-stage biopharma company developing an innovative monoclonal antibody for ophthalmic indications

Sector

Biotechnology

Status
Current Portfolio
Year Invested
2017
GMS Ownership
JV with Tenshi Lifesciences (“BioLexis”) owns ~51%
Re-positioned company from a biosimilars manufacturer to an innovative drug developer